Interleukin-6 Receptor Antagonist [EPC]

135294 reported adverse events

Drugs of this class: TOCILIZUMAB TOCILIZUMAB-AAZG SARILUMAB

These side effects are most commonly reported by patients taking drugs of the Interleukin-6 Receptor Antagonist [EPC] class:

# Side effect Count
0 DRUG INEFFECTIVE 38831
1 RHEUMATOID ARTHRITIS 24620
2 PAIN 23602
3 OFF LABEL USE 21043
4 ARTHRALGIA 20503
5 JOINT SWELLING 18268
6 FATIGUE 16393
7 RASH 14548
8 DRUG INTOLERANCE 13274
9 CONTRAINDICATED PRODUCT ADMINISTERED 12302
See all common reactions for Interleukin-6 Receptor Antagonist [EPC]

Drugs of the Interleukin-6 Receptor Antagonist [EPC] class are most commonly taken among patients reporting these side effects:

# Side effect Count Frequency
0 HUMAN ANTICHIMERIC ANTIBODY POSITIVE 310 0.9254
1 DISABILITY ASSESSMENT SCALE SCORE INCREASED 268 0.8730
2 ANTI-CYCLIC CITRULLINATED PEPTIDE ANTIBODY POSITIVE 6031 0.8597
3 SWOLLEN JOINT COUNT INCREASED 2571 0.8350
4 ANTI-CYCLIC CITRULLINATED PEPTIDE ANTIBODY 544 0.8255
5 RHEUMATOID FACTOR POSITIVE 4633 0.8137
6 RHEUMATIC FEVER 3438 0.7973
7 RHEUMATOID FACTOR NEGATIVE 138 0.7886
8 PEMPHIGUS 9358 0.7625
9 DEEP VEIN THROMBOSIS POSTOPERATIVE 1458 0.7527
See all enriched reactions for Interleukin-6 Receptor Antagonist [EPC]